SOURCE: Immunovative Inc.

Immunovative Inc.

June 05, 2012 06:00 ET

Immunovative, Inc. Announces That ASCO Abstract "Response of HER2+ Breast Cancer Patients to Allogeneic Cell Immunotherapy" Available On-Line

DR. Michael Har-Noy to Present Abstract at ASCO Annual 2012 Meeting in Chicago

NEW YORK, NY--(Marketwire - Jun 5, 2012) - Immunovative, Inc. ("IMUN") (OTCBB: IMUN) today announced that an abstract reporting the results of IMUN's licensor, Immunovative Therapies, Ltd.'s, FDA-approved phase I/II clinical trial of 42 refractory metastatic solid tumor patients with a variety of indications. Although no objective tumor response was observed, there was evidence of enhanced survival and immune-mediated tumor debulking without graft-versus-host disease. Responsive Evaluation Criteria in Solid Tumors overestimated tumor burden, as responding tumors swelled and appeared larger on CT. Multi-parameter analysis identified serum IL-12 as a predictor of enhanced survival. 50% were IL-12+ and survived a median of 211 days vs. 131 days for IL-12- patients (p < .009). The Abstract (Number e13013) titled: "Response of HER2+ Breast Cancer Patients to Allogenic Cell Immunotherapy" is now available on on-line at the American Society of Clinical Oncology Meeting ("ASCO 2012") website at:

Dr. Michael Har-Noy will further comment on these results at ASCO 2012 at the McCormick Place Convention Center in Chicago. To meet with Dr. Har-Noy at ASCO 2101, please contact Antonio Treminio, CEO of IMUN at 212-315-9705 or

About Immunovative, Inc.: On December 15, 2011, Immunovative, Inc. ("IMUN") (then known as Novo Energies Corp.) signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including.

About Immunovative Therapies, Ltd.: Immunovative Therapies, Ltd. ("ITL") is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. ITL is developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer. ITL has two experimental immunotherapy products for the treatment of cancer in clinical development: AlloStim™ and AlloVax™ covered by Immunovative's 10 U.S. patents granted, 15 U.S. patents pending and 26 corresponding applications pending internationally. Please visit ITL's website at:

DISCLAIMER Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.

Contact Information

  • Contact:
    For more information, please contact:

    Mr. Antonio Treminio
    Chairman & Chief Executive Officer
    Immunovative, Inc.
    New York: +1-212-315-9705
    Montreal: +1-514-840-3697
    Email: Email Contact

    Dr. Michael Har-Noy
    Founder & Chief Executive Officer
    Immunovative Therapies, Ltd.
    Israel Tel: +972-2-6506288
    US Tel: +1-760-444-9040
    Email: Email Contact